Moderna COVID-19 vaccine - versus control - for COVID-19 prophylaxis pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

confirmed Covid-19, from 1st dose 0.05 [0.03, 0.09]< 10%1 study (1/-)100.0 %some concernnot evaluable moderatecrucial-
deaths 0.50 [0.02, 14.84]< 10%1 study (1/-)65.4 %some concernnot evaluable moderatecrucial-
vaccine efficacy from randomization (ITT) 0.07 [0.04, 0.11]< 10%1 study (1/-)100.0 %some concernnot evaluable moderatecrucial-
laboratory-confirmed Covid-19 0.06 [0.03, 0.11]< 10%1 study (1/-)100.0 %some concernnot evaluable moderateimportant-
severe COVID-19 occurrence 0.02 [0.00, 0.27]< 10%1 study (1/-)99.8 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.04 [0.78, 1.40]< 10%1 study (1/-)38.6 %some concernnot evaluable moderateimportant-
adverse events 1.14 [1.08, 1.20]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-

AE of interest endpoints 00

appendicitis 0.67 [0.11, 3.99]< 10%1 study (1/-)67.1 %some concernnot evaluable moderatenon important-
arthralgia, grade 3-4 18.37 [13.54, 24.91]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-
fever, grade 3-4 43.29 [17.83, 105.10]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-
hypersensitivity, all terms 1.41 [1.15, 1.72]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-
lymphadenopathy, grade 3-4 3.51 [2.11, 5.85]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-
musculoskeletal and connective tissue disorders, any 1.00 [0.06, 15.97]< 10%1 study (1/-)50.0 %some concernnot evaluable moderatenon important-
myalgia, grade 3-4 27.64 [20.93, 36.50]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-

reactogenicity (vaccines) endpoints 00

local adverse reaction, any, dose 2 33.74 [31.59, 36.03]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-
local adverse reaction, grade 3-4, dose 2 15.04 [11.83, 19.12]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-
systemic adverse reaction, any, dose 2 6.69 [6.35, 7.05]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-
systemic adverse reaction, grade 3-4, dose 2 9.50 [8.38, 10.77]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.